{"id":249683,"date":"2023-12-28T00:00:00","date_gmt":"2023-12-28T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0010-2023-biopharma-bipolar-disorder-landscape-forecast-disease\/"},"modified":"2026-04-24T11:19:21","modified_gmt":"2026-04-24T11:19:21","slug":"dlsfcg0010-2023-biopharma-bipolar-disorder-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0010-2023-biopharma-bipolar-disorder-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Bipolar Disorder &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast"},"content":{"rendered":"<p>Bipolar disorder (<abbr title=\"bipolar disorder\">BPD<\/abbr>) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (<abbr title=\"antiepileptic drug\">AED<\/abbr>s), and antidepressants are the mainstay therapies used to treat <abbr title=\"bipolar disorder\">BPD<\/abbr>; their long-standing stronghold as patient-share leaders contribute to the challenges that branded therapies face entering this crowded therapy market. Nevertheless, current treatments have multiple shortcomings; thus, novel therapies with the potential to capitalize on the remaining opportunities in <abbr title=\"bipolar disorder\">BPD<\/abbr> treatment could drive growth of this market. In addition to newer-to-market antipsychotics (e.g., Alkermes\u2019s Lybalvi, Intra-Cellular Therapies\u2019 Caplyta), a handful of emerging therapies from a variety of drug classes are in late-phase development (e.g., Vanda Pharmaceuticals\u2019 iloperidone, NeuroRx\u2019s NRX-101, Sunovion \/ Sumitomo Dainippon \/ Otsuka\u2019s SEP-4199), and still more are in early development (e.g., psychedelics). If successful, they could offer new treatment options for <abbr title=\"bipolar disorder\">BPD<\/abbr>.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the current size of the <abbr title=\"bipolar disorder\">BPD<\/abbr> therapy market in the G7 countries? What key events will influence the market over the next decade?<\/li>\n<li>What is the epidemiology of <abbr title=\"bipolar disorder\">BPD<\/abbr> in the G7 countries? What percentage of prevalent patients are diagnosed and drug-treated?<\/li>\n<li>What factors drive and constrain the use of branded atypical antipsychotics in the treatment of <abbr title=\"bipolar disorder\">BPD<\/abbr>? Which branded therapy is expected to experience the most commercial success during the forecast period?<\/li>\n<li>What are the greatest areas of unmet need in the treatment of <abbr title=\"bipolar disorder\">BPD<\/abbr>, and how are emerging therapies expected to address these unmet needs?<\/li>\n<\/ul>\n<p><strong>Geographies:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research: <\/strong>19 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this research<\/p>\n<p><strong>Epidemiology: <\/strong>Lifetime<strong>\u00a0<\/strong>prevalence,<strong>\u00a0<\/strong>diagnosed prevalence, and drug-treated prevalence of <abbr title=\"bipolar disorder\">BPD<\/abbr> by country<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key <abbr title=\"bipolar disorder\">BPD<\/abbr> therapies through 2032, segmented by brands \/ generics<\/p>\n<p><strong>Emerging therapies: <\/strong>Preregistration<strong> <\/strong>\/<strong>\u00a0<\/strong>Phase 3: 5 drugs; coverage of select early-phase products<\/p>\n<div>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancements<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Additionally, Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-249683","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bipolar-disorder","biopharma-therapy-areas-psychiatry","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249683\/revisions"}],"predecessor-version":[{"id":575993,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249683\/revisions\/575993"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}